TY - JOUR
T1 - Blockade of NF-κB improves cardiac function and survival without affecting inflammation in TNF-α-induced cardiomyopathy
AU - Kawamura, Natsumi
AU - Kubota, Toru
AU - Kawano, Shunichi
AU - Monden, Yoshiya
AU - Feldman, Arthur M.
AU - Tsutsui, Hiroyuki
AU - Takeshita, Akira
AU - Sunagawa, Kenji
N1 - Funding Information:
A part of this study was conducted in Kyushu University Station for Collaborative Research. This study was supported by a grant from Kimura Memorial Heart Foundation, by the Grant for Research on Cardiovascular Disease from Japan Heart Foundation/Pfizer Pharmaceuticals Inc., and by the Grant-in-Aid for Scientific Research from the Japan Society for the promotion of Science (C15590755).
PY - 2005/6/1
Y1 - 2005/6/1
N2 - Objective: NF-κB, a key transcription factor that regulates inflammatory processes, has been shown to be activated in the failing human heart with enhanced expression of proinflammatory cytokines. In the present study, we assessed the hypothesis that cardiotoxic effects of proinflammatory cytokines are mediated by the activation of NF-κB. Methods: Transgenic mice with cardiac-specific overexpression of TNF-α were used as a model of cytokine-induced cardiomyopathy. To block the activation of NF-κB, transgenic mice (TG/p50+/+) were crossed with knockout mice in which the p50 subunit of NF-κB was disrupted (WT/p50-/-). Results: The electrophoretic mobility shift assay demonstrated that NF-κB was activated in the myocardium of TG/p50+/+ mice, while it was completely abolished in TG/p50-/- mice. Male TG mice died of congestive heart failure earlier than females, where the disruption of the p50 subunit significantly improved the survival. Compared with TG/p50+/+ mice, TG/p50-/- mice showed a significant reduction of ventricular dilatation and hypertrophy with preserved fractional shortening. Although the myocardial expression of proinflammatory cytokines or infiltration of inflammatory cells was not affected, increased expression and activity of MMP-9 were significantly suppressed in TG/p50-/- mice. Conclusion: Blockade of NF-κB activation did not ameliorate myocardial inflammation but improved cardiac function and survival in male TNF-α TG mice. An inhibition of NF-κB may be a new therapeutic strategy for cardiac remodeling and heart failure, especially when proinflammatory cytokines are activated.
AB - Objective: NF-κB, a key transcription factor that regulates inflammatory processes, has been shown to be activated in the failing human heart with enhanced expression of proinflammatory cytokines. In the present study, we assessed the hypothesis that cardiotoxic effects of proinflammatory cytokines are mediated by the activation of NF-κB. Methods: Transgenic mice with cardiac-specific overexpression of TNF-α were used as a model of cytokine-induced cardiomyopathy. To block the activation of NF-κB, transgenic mice (TG/p50+/+) were crossed with knockout mice in which the p50 subunit of NF-κB was disrupted (WT/p50-/-). Results: The electrophoretic mobility shift assay demonstrated that NF-κB was activated in the myocardium of TG/p50+/+ mice, while it was completely abolished in TG/p50-/- mice. Male TG mice died of congestive heart failure earlier than females, where the disruption of the p50 subunit significantly improved the survival. Compared with TG/p50+/+ mice, TG/p50-/- mice showed a significant reduction of ventricular dilatation and hypertrophy with preserved fractional shortening. Although the myocardial expression of proinflammatory cytokines or infiltration of inflammatory cells was not affected, increased expression and activity of MMP-9 were significantly suppressed in TG/p50-/- mice. Conclusion: Blockade of NF-κB activation did not ameliorate myocardial inflammation but improved cardiac function and survival in male TNF-α TG mice. An inhibition of NF-κB may be a new therapeutic strategy for cardiac remodeling and heart failure, especially when proinflammatory cytokines are activated.
UR - http://www.scopus.com/inward/record.url?scp=19444361810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19444361810&partnerID=8YFLogxK
U2 - 10.1016/j.cardiores.2005.02.007
DO - 10.1016/j.cardiores.2005.02.007
M3 - Article
C2 - 15914117
AN - SCOPUS:19444361810
SN - 0008-6363
VL - 66
SP - 520
EP - 529
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 3
ER -